Monocyte programming by cancer therapy
Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenviro...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 October 2022
|
| In: |
Frontiers in immunology
Year: 2022, Volume: 13, Pages: 1-21 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2022.994319 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2022.994319 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2022.994319 
|
| Author Notes: | Marina Patysheva, Anastasia Frolova, Irina Larionova, Sergey Afanas'ev, Anna Tarasova, Nadezhda Cherdyntseva and Julia Kzhyshkowska |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 185682277X | ||
| 003 | DE-627 | ||
| 005 | 20251127132607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230821s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.994319 |2 doi | |
| 035 | |a (DE-627)185682277X | ||
| 035 | |a (DE-599)KXP185682277X | ||
| 035 | |a (OCoLC)1425216623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Patysheva, Marina |e VerfasserIn |0 (DE-588)1208018167 |0 (DE-627)1694318729 |4 aut | |
| 245 | 1 | 0 | |a Monocyte programming by cancer therapy |c Marina Patysheva, Anastasia Frolova, Irina Larionova, Sergey Afanas'ev, Anna Tarasova, Nadezhda Cherdyntseva and Julia Kzhyshkowska |
| 264 | 1 | |c 20 October 2022 | |
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.08.2023 | ||
| 520 | |a Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenvironment that control disease outcome and efficiency of cancer therapy. Four major types of anti-cancer therapy, surgery, radiotherapy, chemotherapy, and most recent immunotherapy, affect tumor-associated macrophage (TAM) polarization and functions. TAMs can also decrease the efficiency of therapy in a tumor-specific way. Monocytes is a major source of TAMs, and are recruited to tumor mass from the blood circulation. However, the mechanisms of monocyte programming in circulation by different therapeutic onsets are only emerging. In our review, we present the state-of-the art about the effects of anti-cancer therapy on monocyte progenitors and their dedifferentiation, on the content of monocyte subpopulations and their transcriptional programs in the circulation, on their recruitment into tumor mass and their potential to give origin for TAMs in tumor-specific microenvironment. We have also summarized very limited available knowledge about genetics that can affect monocyte interaction with cancer therapy, and highlighted the perspectives for the therapeutic targeting of circulating monocytes in cancer patients. We summarized the knowledge about the mediators that affect monocytes fate in all four types of therapies, and we highlighted the perspectives for targeting monocytes to develop combined and minimally invasive anti-cancer therapeutic approaches. | ||
| 700 | 1 | |a Frolova, Anastasia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larionova, Irina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Afanas'ev, Sergey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tarasova, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cherdyntseva, Nadezhda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kzhyshkowska, Julia |d 1967- |e VerfasserIn |0 (DE-588)102414271X |0 (DE-627)719213754 |0 (DE-576)368002233 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 13(2022) vom: Okt., Artikel-ID 994319, Seite 1-21 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a Monocyte programming by cancer therapy |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g month:10 |g elocationid:994319 |g pages:1-21 |g extent:21 |a Monocyte programming by cancer therapy |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2022.994319 |x Resolving-System |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2022.994319 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230821 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 102414271X |a Kzhyshkowska, Julia |m 102414271X:Kzhyshkowska, Julia |d 60000 |d 63500 |e 60000PK102414271X |e 63500PK102414271X |k 0/60000/ |k 1/60000/63500/ |p 7 |y j | ||
| 999 | |a KXP-PPN185682277X |e 4368551826 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Marina Patysheva, Anastasia Frolova, Irina Larionova, Sergey Afanas'ev, Anna Tarasova, Nadezhda Cherdyntseva and Julia Kzhyshkowska"]},"id":{"doi":["10.3389/fimmu.2022.994319"],"eki":["185682277X"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"20 October 2022"}],"person":[{"display":"Patysheva, Marina","role":"aut","given":"Marina","family":"Patysheva"},{"given":"Anastasia","role":"aut","family":"Frolova","display":"Frolova, Anastasia"},{"display":"Larionova, Irina","family":"Larionova","given":"Irina","role":"aut"},{"display":"Afanas'ev, Sergey","family":"Afanas'ev","role":"aut","given":"Sergey"},{"role":"aut","given":"Anna","family":"Tarasova","display":"Tarasova, Anna"},{"role":"aut","given":"Nadezhda","family":"Cherdyntseva","display":"Cherdyntseva, Nadezhda"},{"display":"Kzhyshkowska, Julia","role":"aut","given":"Julia","family":"Kzhyshkowska"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"657998354","disp":"Monocyte programming by cancer therapyFrontiers in immunology","pubHistory":["1.2010 -"],"origin":[{"publisherPlace":"Lausanne","dateIssuedKey":"2010","dateIssuedDisp":"2010-","publisher":"Frontiers Media"}],"note":["Gesehen am 07.11.13"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"text":"13(2022) vom: Okt., Artikel-ID 994319, Seite 1-21","volume":"13","extent":"21","pages":"1-21","year":"2022"},"title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}],"id":{"issn":["1664-3224"],"eki":["657998354"],"zdb":["2606827-8"]}}],"title":[{"title_sort":"Monocyte programming by cancer therapy","title":"Monocyte programming by cancer therapy"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 21.08.2023"],"recId":"185682277X","physDesc":[{"extent":"21 S."}]} | ||
| SRT | |a PATYSHEVAMMONOCYTEPR2020 | ||